Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million

Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross proceeds, the company has now doubled the offering to $20.0 million on the back of strong demand.

The financing will see units of the company sold at a price of $0.50 per unit, with each unit containing one common share and one common share purchase warrant with an exercise price of $0.70, valid for a period of three years.

Warrants issued under the financing also contain an acceleration clause, enabling the company to accelerate the expiry of the warrants should the equity trade above $1.10 for a period of ten days on a volume weighted basis. A 15% over-allotment option has also been granted to the underwriters.

Proceeds from the financing are to be used for phase 3 clinical trials of the use of Bucillamine in the treatment of COVID-19, as well as phase 1 clinical trials for psilocybin for methamphetamine use disorder. Funding will also be used for other psychedelic formulation development as well as working capital and general corporate purposes.

Revive Therapeutics last traded at $0.60 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Revive Therapeutics Looks To Bring Bucillamine To India

Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it...

Tuesday, June 8, 2021, 09:15:00 AM

Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to...

Thursday, June 17, 2021, 08:45:27 AM

Revive Explores Use of Bucillamine For Infectious Disease

Revive Therapeutics (CSE: RVV) announced this morning that it has applied for a provisional patent...

Friday, March 20, 2020, 08:28:56 AM

Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug...

Friday, April 3, 2020, 10:44:10 AM

Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive...

Wednesday, August 18, 2021, 09:23:10 AM